Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients COVID-19, Uncategorized Media & Investor Release Roche and Atea partner to jointly develop AT-527, an orally administered direct-acting antiviral (DAA) currently in Phase 2 clinical trials AT-527 has the potential to be the first novel oral antiviral to treat COVID-19 patients outside the hospital setting as well as in the hospital and may also be used in post-exposure Details Journey to learn motivates Milica Gavrilović to seek CMP-HC certification ABTS Upon earning her CMP in 2014, Milica says she saw an immediate impact on her skillset and ability to do her job. “It helped me speak with managers from around the world using the same language,” she said. Five years later, she knew that she wanted to continue her learning journey through the CMP-HC curriculum and certification due to the nature of her work with medical professionals. Details Medical Meetings Post-COVID Plan, NOW COVID-19, Uncategorized In the last couple of months, I have read many articles about COVID-19 and its effect on the meetings, travel, and hospitality industries. In the beginning, the articles were akin to yellow journalism: the world was going to end, and we were all going to die or at least go bankrupt. Slowly, articles became more Details Planning for an Age of Uncertainty: A Meeting Planner’s Perspective Uncategorized As meeting professionals, we love to plan every detail of our event. We know our targets, we scrutinize our attendees, and we consider every possibility before it happens. I have changed the setup of a meeting space at the last minute based on the number of attendees: not too empty, not too crowded. I have Details GO LIVE TOGETHER ABTS ABTS announces its support as a partner for Go LIVE Together, representing over 4,000 companies with U.S. operations—who have joined forces to support legislative actions that will aid the industry’s recovery from COVID-19. The coalition is bound together by the belief that nothing in the world will ever replace the power and need for trade Details A Great Desire for Normalcy Uncategorized The question is easy: If you are part of the hospitality industry and you could make a wish, what would it be? My guess is your answer resembles mine: “Let’s call to Dr. Emmett Brown, jump into his DeLorean, push the accelerator to 88 mph and go back in time. Date and location? Easy answer: Details The International Twist Uncategorized ~ Davide Veglia With the COVID19 pandemic and the cancellation of many meetings and events, meeting planners are faced with the challenge of mitigating financial losses as well as maintaining brand fidelity with attendees. The entire travel service community is suffering and struggling to survive. Everyone involved: airlines, hotels, transportation, housing, exhibition, and registration companies Details Why virtual events should not be replacing live experiences ABTS In 2015 I worked on the production and organization of a series of educational events focused on hospital-acquired infections specifically for the Latin American market. We developed a whole strategy with particular attention to maximizing brand awareness and increasing revenues for the nonprofit organizer. Medical sponsors bought packages of multiple registrations and invited medical professionals Details Roche to present new and updated data for seven approved and investigational medicines across multiple types of breast cancer at the 2019 San Antonio Breast Cancer Symposium Uncategorized Media Release Basel, 18 November 2019 Study results reflect advancements in HER2-positive, triple-negative, and hormone receptor-positive breast cancer Follow-up data from pivotal phase III APHINITY study evaluating Perjeta plus Herceptin and chemotherapy in HER2-positive early breast cancer Results from phase III FeDeriCa study confirming the non-inferiority of a fixed-dose combination of Perjeta and Herceptin administered Details Japan becomes the first country to approve Roche’s personalized medicine Rozlytrek Uncategorized Media Release Basel, 18 June 2019 First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours Approval supported by the data mainly from the pivotal Phase II STARTRK-2 study showing that Rozlytrek shrank tumours in more than half of people with NTRK fusion-positive solid tumours, across 10 Details 1 2 3 MIAMI BELGRADE © ABTS convention services, All Rights Reserved I Privacy Policy